Luke Sergott
Stock Analyst at Barclays
(3.22)
# 1,074
Out of 5,141 analysts
379
Total ratings
45.39%
Success rate
2.2%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRL Charles River Laboratories International | Maintains: Overweight | $215 → $200 | $168.92 | +18.40% | 12 | Feb 19, 2026 | |
| WST West Pharmaceutical Services | Maintains: Equal-Weight | $325 → $265 | $241.12 | +9.90% | 5 | Feb 13, 2026 | |
| BRKR Bruker | Maintains: Overweight | $55 → $50 | $38.28 | +30.62% | 9 | Feb 13, 2026 | |
| AVTR Avantor | Maintains: Equal-Weight | $12 → $9 | $9.03 | -0.33% | 28 | Feb 12, 2026 | |
| MEDP Medpace Holdings | Maintains: Underweight | $525 → $500 | $453.77 | +10.19% | 6 | Feb 11, 2026 | |
| WAT Waters | Reinstates: Overweight | $400 | $333.33 | +20.00% | 19 | Feb 11, 2026 | |
| IQV IQVIA Holdings | Maintains: Equal-Weight | $230 → $210 | $165.62 | +26.80% | 25 | Feb 6, 2026 | |
| TWST Twist Bioscience | Maintains: Overweight | $39 → $50 | $48.59 | +2.90% | 21 | Feb 3, 2026 | |
| RVTY Revvity | Maintains: Overweight | $115 → $118 | $100.33 | +17.61% | 13 | Feb 3, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $625 → $650 | $510.93 | +27.22% | 30 | Jan 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $52 | $48.57 | +7.84% | 3 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $175 → $200 | $135.68 | +47.41% | 4 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1.5 → $2 | $1.61 | +24.22% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $230 → $270 | $212.12 | +27.29% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,600 → $1,550 | $1,377.55 | +12.52% | 4 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $100 → $110 | $117.67 | -6.52% | 22 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $185 → $200 | $99.70 | +100.60% | 23 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $120 | $103.10 | +16.39% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $13 | $6.46 | +101.24% | 20 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $22 | $18.88 | +16.53% | 15 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $10 → $15 | $11.00 | +36.36% | 14 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $165 | $122.90 | +34.26% | 14 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $77 → $105 | $103.43 | +1.52% | 9 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $20 | $17.49 | +14.35% | 23 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $225 → $250 | $209.50 | +19.33% | 41 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $101.32 | -11.17% | 1 | Aug 1, 2025 |
Charles River Laboratories International
Feb 19, 2026
Maintains: Overweight
Price Target: $215 → $200
Current: $168.92
Upside: +18.40%
West Pharmaceutical Services
Feb 13, 2026
Maintains: Equal-Weight
Price Target: $325 → $265
Current: $241.12
Upside: +9.90%
Bruker
Feb 13, 2026
Maintains: Overweight
Price Target: $55 → $50
Current: $38.28
Upside: +30.62%
Avantor
Feb 12, 2026
Maintains: Equal-Weight
Price Target: $12 → $9
Current: $9.03
Upside: -0.33%
Medpace Holdings
Feb 11, 2026
Maintains: Underweight
Price Target: $525 → $500
Current: $453.77
Upside: +10.19%
Waters
Feb 11, 2026
Reinstates: Overweight
Price Target: $400
Current: $333.33
Upside: +20.00%
IQVIA Holdings
Feb 6, 2026
Maintains: Equal-Weight
Price Target: $230 → $210
Current: $165.62
Upside: +26.80%
Twist Bioscience
Feb 3, 2026
Maintains: Overweight
Price Target: $39 → $50
Current: $48.59
Upside: +2.90%
Revvity
Feb 3, 2026
Maintains: Overweight
Price Target: $115 → $118
Current: $100.33
Upside: +17.61%
Thermo Fisher Scientific
Jan 30, 2026
Maintains: Overweight
Price Target: $625 → $650
Current: $510.93
Upside: +27.22%
Dec 15, 2025
Maintains: Overweight
Price Target: $50 → $52
Current: $48.57
Upside: +7.84%
Dec 15, 2025
Maintains: Overweight
Price Target: $175 → $200
Current: $135.68
Upside: +47.41%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $1.5 → $2
Current: $1.61
Upside: +24.22%
Dec 15, 2025
Maintains: Overweight
Price Target: $230 → $270
Current: $212.12
Upside: +27.29%
Dec 15, 2025
Maintains: Overweight
Price Target: $1,600 → $1,550
Current: $1,377.55
Upside: +12.52%
Dec 15, 2025
Maintains: Underweight
Price Target: $100 → $110
Current: $117.67
Upside: -6.52%
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $185 → $200
Current: $99.70
Upside: +100.60%
Dec 15, 2025
Maintains: Overweight
Price Target: $85 → $120
Current: $103.10
Upside: +16.39%
Dec 15, 2025
Maintains: Overweight
Price Target: $14 → $13
Current: $6.46
Upside: +101.24%
Dec 15, 2025
Maintains: Overweight
Price Target: $17 → $22
Current: $18.88
Upside: +16.53%
Dec 15, 2025
Upgrades: Equal-Weight
Price Target: $10 → $15
Current: $11.00
Upside: +36.36%
Dec 15, 2025
Upgrades: Overweight
Price Target: $165
Current: $122.90
Upside: +34.26%
Nov 21, 2025
Downgrades: Equal-Weight
Price Target: $77 → $105
Current: $103.43
Upside: +1.52%
Nov 5, 2025
Maintains: Overweight
Price Target: $19 → $20
Current: $17.49
Upside: +14.35%
Oct 22, 2025
Maintains: Overweight
Price Target: $225 → $250
Current: $209.50
Upside: +19.33%
Aug 1, 2025
Initiates: Overweight
Price Target: $90
Current: $101.32
Upside: -11.17%